Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Macro­Gen­ics and Ab­b­Vie plan to end de­vel­op­ment of their ADAM9-tar­get­ed an­ti­body-drug con­ju­gate af­ter ear­ly tri­al da­ta dis­ap­point­ed.

The Mary­land-based Macro­Gen­ics said the ADC, known as IMGC936, “did not achieve pre-es­tab­lished clin­i­cal safe­ty and ef­fi­ca­cy bench­marks.”

Im­muno­Gen had led the clin­i­cal de­vel­op­ment of IMGC936 and com­plet­ed the Phase I stud­ies. Ab­b­Vie bought the ADC drug­mak­er for $10.1 bil­lion in No­vem­ber. Im­muno­Gen and Macro­Gen­ics had a 50/50 col­lab­o­ra­tion on the as­set.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER